💊FDA PHARMA TODAY
Encorafenib and Binimetinib Combination Treatment
Demonstrates 33.6 Month Median Overall Survival (OS) in Patients
with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
http://www.ono.co.jp/eng/news/pdf/sm_cn180207.pdf
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS)
with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell
Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)